The Danish biotech company Concit Pharma has gained the opportunity to help remedy the debilitating movement disorders associated with Parkinson’s disease within a number of years. In pre-clinical trials the company has documented significant effects of treating this disorder with a combination of already known drugs, and has now raised € 1.3 million to pursue this path further.

One percent of the entire population over 60 years is infected with Parkinson’s disease. The illness is chronic and characterized by muscle stiffness, shaking and reduced movements. There are today a number of ways of treating Parkinson’s, which makes it possible to control the illness for many years, however a result of the medical treatment is the side effect dyskinesia for more than half of all patients. Dyskinesia is characterized by involuntary and uncontrollable movements.

Over a significant time span the researchers behind Concit Pharma has researched Dyskinesia and are now announcing, that they – by combining already known drugs – have found a drug combination, which could prove to remedy this debilitating illness. The combination is now well documented in rats and patented. The two founders – John Bondo Hansen & Mikael Thomsen – will now begin to optimize the drug combination and expect to begin clinical trials on humans next year.

Just recently Concit Pharma has also added Dr. Magnus Persson to their board. Magnus Persson has a wide reaching network and an impressive career within Life Science, where he has successfully founded, managed and financed a large number of companies. On the board is already Dr. Sissel Vorstrup who is former consultant doctor at Rigshospitalet and President of Clinical Development at Lundbeck.

In connection to the impressive results Concit Pharma’s two current investors – SEED Capital and Novo Seeds – has invested an additional € 1.3 million in the company. The investment will be used on optimizing the drug combination in preparation of clinical trials on humans.